The decision to administer recombinant erythropoietins should be based on a benefit-risk assessment with the participation of the individual patient, which should take into account the specific clinical context.
Otsus rekombinantse erütropoetiini manustamiseks peab põhinema individuaalse patsiendi osalusel tehtud kasu- ohu hinnangul, mis arvestab spetsiifilist kliinilist konteksti.